Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront in its third deal since February. Plus FDA lifts MacroGenics hold, AbbVie sues over 340B, and Vanda targets GLP-1 side effects with theThetis trial.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Foundayo, oral GLP-1, Novo Nordisk, Gilead Sciences, Tubulis, ADC, antibody-drug conjugate, MacroGenics, lorigerlimab, Vanda Pharmaceuticals, tradipitant, Nereus, AbbVie, 340B, PhRMA, Steven Ubl, Roche, C4 Therapeutics,DAC, Garda, Assertio, Rolvedon, Kyverna, KYSA-8, Invivyd, measles, Shionogi, BARDA, GoodRx, Lilly, GSK, BMS, Gilead
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →